Coherus Oncology (CHRS) Leases (2019 - 2024)
Historic Leases for Coherus Oncology (CHRS) over the last 7 years, with Q4 2024 value amounting to $4.5 million.
- Coherus Oncology's Leases fell 2357.92% to $4.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 million, marking a year-over-year decrease of 2357.92%. This contributed to the annual value of $4.5 million for FY2024, which is 2357.92% down from last year.
- Latest data reveals that Coherus Oncology reported Leases of $4.5 million as of Q4 2024, which was down 2357.92% from $5.9 million recorded in Q4 2023.
- Coherus Oncology's 5-year Leases high stood at $11.5 million for Q1 2020, and its period low was $4.5 million during Q4 2024.
- Over the past 5 years, Coherus Oncology's median Leases value was $9.4 million (recorded in 2021), while the average stood at $8.5 million.
- As far as peak fluctuations go, Coherus Oncology's Leases skyrocketed by 7313.08% in 2020, and later crashed by 3055.05% in 2022.
- Quarter analysis of 5 years shows Coherus Oncology's Leases stood at $10.0 million in 2020, then decreased by 17.71% to $8.2 million in 2021, then plummeted by 30.55% to $5.7 million in 2022, then grew by 3.9% to $5.9 million in 2023, then decreased by 23.58% to $4.5 million in 2024.
- Its last three reported values are $4.5 million in Q4 2024, $5.9 million for Q4 2023, and $5.7 million during Q4 2022.